Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CDKN2A mutation
i
Other names:
CDKN2A, ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf, Cyclin-dependent kinase inhibitor 2A
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1029
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
CDKN2A mutation
Squamous Cell Carcinoma of Head and Neck
CDKN2A mutation
Squamous Cell Carcinoma of Head and Neck
palbociclib
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days (New C3)
palbociclib
Sensitive
:
C3
ASCO 2023 - 3d
palbociclib
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
palbociclib
Sensitive
:
C3
ASCO 2023 - 3 days - (New C3)
CDKN2A mutation
Triple Negative Breast Cancer
CDKN2A mutation
Triple Negative Breast Cancer
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
atezolizumab
Sensitive: B - Late Trials
atezolizumab
Sensitive
:
B
CDKN2A mutation
Breast Cancer
CDKN2A mutation
Breast Cancer
ribociclib
Resistant: B - Late Trials
ribociclib
Resistant
:
B
ribociclib
Resistant: B - Late Trials
ribociclib
Resistant
:
B
CDKN2A mutation
Gallbladder Cancer
CDKN2A mutation
Gallbladder Cancer
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
CDKN2A mutation
Clear Cell Renal Cell Carcinoma
CDKN2A mutation
Clear Cell Renal Cell Carcinoma
palbociclib
Sensitive: C3 – Early Trials
palbociclib
Sensitive
:
C3
palbociclib
Sensitive: C3 – Early Trials
palbociclib
Sensitive
:
C3
CDKN2A mutation
Pancreatic Cancer
CDKN2A mutation
Pancreatic Cancer
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
palbociclib
Resistant: C3 – Early Trials
palbociclib
Resistant
:
C3
CDKN2A mutation
Solid Tumor
CDKN2A mutation
Solid Tumor
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
CDKN2A mutation
Melanoma
CDKN2A mutation
Melanoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
CDKN2A mutation
Urothelial Cancer
CDKN2A mutation
Urothelial Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
CDKN2A mutation
Biliary Tract Cancer
CDKN2A mutation
Biliary Tract Cancer
toripalimab
Resistant: C3 – Early Trials
toripalimab
Resistant
:
C3
toripalimab
Resistant: C3 – Early Trials
toripalimab
Resistant
:
C3
CDKN2A mutation
Non Small Cell Lung Cancer
CDKN2A mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
CDKN2A mutation
Penile Cancer
CDKN2A mutation
Penile Cancer
nivolumab
Sensitive: C4 – Case Studies
nivolumab
Sensitive
:
C4
nivolumab
Sensitive: C4 – Case Studies
nivolumab
Sensitive
:
C4
CDKN2A mutation
Squamous Cell Carcinoma of Head and Neck
CDKN2A mutation
Squamous Cell Carcinoma of Head and Neck
AZD1775 + VIC-1911
Sensitive: D – Preclinical
AZD1775 + VIC-1911
Sensitive
:
D
AZD1775 + VIC-1911
Sensitive: D – Preclinical
AZD1775 + VIC-1911
Sensitive
:
D
CDKN2A mutation
Non Small Cell Lung Cancer
CDKN2A mutation
Non Small Cell Lung Cancer
AZD1775 + VIC-1911
Sensitive: D – Preclinical
AZD1775 + VIC-1911
Sensitive
:
D
AZD1775 + VIC-1911
Sensitive: D – Preclinical
AZD1775 + VIC-1911
Sensitive
:
D
CDKN2A mutation
Melanoma
CDKN2A mutation
Melanoma
palbociclib
Sensitive: D – Preclinical
palbociclib
Sensitive
:
D
palbociclib
Sensitive: D – Preclinical
palbociclib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login